• English
  • العربية
  • 中文
  • Français
  • Русский
  • Español

You are here

International Conference on Molecular Imaging and Clinical PET–CT in the Era of Theranostics (IPET-2020)

23–27 November 2020, Vienna, Austria

Conference on Molecular Imaging and Clinical PET–CT (IPET-2020)

The International Atomic Energy Agency (IAEA) is organizing the International Conference on Molecular Imaging and Clinical PET–CT in the Era of Theranostics (IPET-2020) following the successes of IPET-2007, IPET-2011, and IPET-2015. Innovation in research and development is a driving force in medical imaging. New imaging devices, radiopharmaceuticals, clinical applications and medical evidence are being produced at a fast pace and need to be propagated.

New standards of best practice should be emphasized, and all efforts should be made to keep the medical community abreast with current developments in order to provide optimal patient care and professional growth. Nuclear medicine and diagnostic imaging play a key role in cancer management. They permit early and accurate diagnoses and precise staging, provide guidelines for selecting the best course of therapy, allowing the treatment to be monitored, and further aid disease management by supporting treatment planning or guided biopsies. Radiopharmaceuticals labelled with alpha or beta emitters, targeting relevant molecular markers expressed by different solid and haematological tumours can be used for radionuclide targeted therapies.Medical imaging and radionuclide therapies, together, help herald in the era of personalized medicine. This conference will provide a forum for clinicians, imaging specialists and scientists to review the important clinical aspects of cancer management. It will critically examine the pivotal role of multimodality imaging techniques, combined with targeted therapies with a view to addressing the health challenges common to many Member States. In addition, special sessions on ethics, leadership, communication, Sustainable Development Goals, radiopharmacy, and medical physics will provide opportunities for participants to review the theoretical tools necessary to bring together nuclear medicine and diagnostic imaging within the sphere of global health.

Objectives

The conference will review important clinical aspects, and the appropriate use, of medical imaging in managing patients with cancers of the prostate, breast, lung, and thyroid, as well as patients with neuroendocrine tumours, lymphoma, and paediatric cancers. The conference will have the following objectives:

  • To review the important clinical aspects of the above-mentioned pathologies, and evaluate the role of streamlined and emerging multimodality imaging techniques in providing best practices in clinical management;
  • To evaluate, using a clinical systems-based approach, the current status of clinical positron emission tomography–computed tomography (PET–CT) and other relevant imaging modalities;
  • To evaluate how complementing diagnostic molecular imaging and radionuclide therapies is key to developing personalized medicine;
  • To improve clinical practice through ‘read with the experts’ sessions and discussions;
  • To interact with the user community (nuclear physicians, radiologists, oncologists, radiation oncologists, technologists, radiographers, radiopharmacists, radiochemists, medical physicists and other scientists working in all aspects of molecular imaging) and provide them with the most important information in the field;
  • To provide theoretical tools on ethics, leadership and education which will prepare participants to become the future leaders of medical imaging;
  • To exchange information concerning radiopharmaceutical sciences; and
  • To identify challenges and trends and to define the role of the IAEA and other international organizations in supporting Member States.

Structure and Topics

Every session will follow a clinical systems-based approach and will include an initial discussion on the important clinical aspects of the disease, or condition, to which the session is devoted. The discussion will be followed by a thorough review of the role of nuclear medicine and diagnostic imaging and the session will conclude with the status of theranostic applications. Each clinical session will be comprised of plenary sessions followed by an interactive ‘read with the experts’ session Sessions for physicists, technologists, radiographers, radiopharmacists and radiochemists will be conducted in parallel. The IAEA invites participants to provide high-quality contributions on all aspects of nuclear medicine, diagnostic imaging, or theranostic applications and research. Academic and practice-based papers that fall within the following topics will be welcomed:

  • Applications of PET–CT, molecular imaging and diagnostic imaging for different types of cancer: breast, lung, colorectal, prostate, neuroendocrine, thyroid, etc.;
  • Theranostics applications;
  • Radio-guided surgery;
  • Hybrid imaging and other imaging techniques in benign conditions;
  • Dosimetry, physics and instrumentation;
  • Radiopharmaceutical production, including good manufacturing practices and quality assurance;
  • Radiation protection for personnel and patients;
  • Quality management in nuclear medicine and diagnostic imaging; 
  • Ethics, leadership and education for nuclear medicine and diagnostic imaging professionals; and 
  • Experience in establishing or strengthening nuclear medicine, diagnostic imaging or radionuclide therapy facilities, including related technical cooperation projects.

Registration procedure

Online registration is closed. However, participation is still possible by sending your completed Participation Form (Form A) through the competent official authority (Ministry of Foreign Affairs or National Atomic Energy Authority) to the IAEA. A participant will be accepted only if the Participation Form is transmitted through the competent official authority of a Member State of the IAEA or by an international organization invited to participate.

Target Audience

This conference will provide the opportunity to review the latest developments in the field of nuclear medicine, diagnostic imaging and theranostics. The target audience is: 

  • Nuclear medicine physicians;
  • Radiologists;
  • Technologists and radiographers;
  • Medical physicists;
  • Radiochemists and radiopharmacists; and
  • Other scientists working in all aspects of molecular imaging.

Key Deadlines and Dates

  • 15 June 2020: Electronic submission of abstract through INDICO
  • 15 June 2020: Submission of Forms A and if applicable B and C through official channels
  • End of June 2020: Notification of acceptance of abstracts
  • No deadline: Submission of Form A only (no paper submission, no grant request)

Greening

To demonstrate its commitment to sustainability, the IAEA will organize this conference as a 'green meeting' according to the guidelines of the Austrian Ecolabel.

There will be a focus on the areas of paper smart documentation, waste reduction and recycling, and environmentally friendly catering.

Live streaming

All sessions, including the opening statements, will be streamed live. A link to the video streaming service will be provided on the opening day.

Conference app

The IAEA Conferences and Meetings App provides a one-stop access to information on the Conference, exhibitions and scheduled side events. The app also allows users to put together their own personalized schedule of events. Via this app participants will be able to view contributed papers and the latest conference programme, message other participants, and view PowerPoint presentations released after the event. Participants will receive an email inviting them to register for the app approximately one week before the conference.

For iPhone or iPad users, get your free download through the Apple iTunes Store; those with Android devices can visit the Google Play Store.

Resources

  1. Employment
  2. Women
  3. Press

Stay in touch

Newsletter